254 related articles for article (PubMed ID: 27267849)
1. CD103 and Intratumoral Immune Response in Breast Cancer.
Wang ZQ; Milne K; Derocher H; Webb JR; Nelson BH; Watson PH
Clin Cancer Res; 2016 Dec; 22(24):6290-6297. PubMed ID: 27267849
[TBL] [Abstract][Full Text] [Related]
2. Tumor-infiltrating lymphocytes expressing the tissue resident memory marker CD103 are associated with increased survival in high-grade serous ovarian cancer.
Webb JR; Milne K; Watson P; Deleeuw RJ; Nelson BH
Clin Cancer Res; 2014 Jan; 20(2):434-44. PubMed ID: 24190978
[TBL] [Abstract][Full Text] [Related]
3. PD-1 and CD103 Are Widely Coexpressed on Prognostically Favorable Intraepithelial CD8 T Cells in Human Ovarian Cancer.
Webb JR; Milne K; Nelson BH
Cancer Immunol Res; 2015 Aug; 3(8):926-35. PubMed ID: 25957117
[TBL] [Abstract][Full Text] [Related]
4. Combined Immunoscore of CD103 and CD3 Identifies Long-Term Survivors in High-Grade Serous Ovarian Cancer.
Bösmüller HC; Wagner P; Peper JK; Schuster H; Pham DL; Greif K; Beschorner C; Rammensee HG; Stevanović S; Fend F; Staebler A
Int J Gynecol Cancer; 2016 May; 26(4):671-9. PubMed ID: 26905331
[TBL] [Abstract][Full Text] [Related]
5. CD103 defines intraepithelial CD8+ PD1+ tumour-infiltrating lymphocytes of prognostic significance in endometrial adenocarcinoma.
Workel HH; Komdeur FL; Wouters MC; Plat A; Klip HG; Eggink FA; Wisman GB; Arts HJ; Oonk MH; Mourits MJ; Yigit R; Versluis M; Duiker EW; Hollema H; de Bruyn M; Nijman HW
Eur J Cancer; 2016 Jun; 60():1-11. PubMed ID: 27038842
[TBL] [Abstract][Full Text] [Related]
6. Functional Heterogeneity of CD4
Oja AE; Piet B; van der Zwan D; Blaauwgeers H; Mensink M; de Kivit S; Borst J; Nolte MA; van Lier RAW; Stark R; Hombrink P
Front Immunol; 2018; 9():2654. PubMed ID: 30505306
[TBL] [Abstract][Full Text] [Related]
7. Prognostic implications of intratumoral CD103+ tumor-infiltrating lymphocytes in pulmonary squamous cell carcinoma.
Koh J; Kim S; Kim MY; Go H; Jeon YK; Chung DH
Oncotarget; 2017 Feb; 8(8):13762-13769. PubMed ID: 28099920
[TBL] [Abstract][Full Text] [Related]
8. CD103+ Tumor Infiltrating Lymphocytes Predict a Favorable Prognosis in Urothelial Cell Carcinoma of the Bladder.
Wang B; Wu S; Zeng H; Liu Z; Dong W; He W; Chen X; Dong X; Zheng L; Lin T; Huang J
J Urol; 2015 Aug; 194(2):556-62. PubMed ID: 25752441
[TBL] [Abstract][Full Text] [Related]
9. Analysis of tumor-infiltrating CD103 resident memory T-cell content in recurrent laryngeal squamous cell carcinoma.
Mann JE; Smith JD; Birkeland AC; Bellile E; Swiecicki P; Mierzwa M; Chinn SB; Shuman AG; Malloy KM; Casper KA; McLean SA; Moyer JS; Wolf GT; Bradford CR; Prince ME; Carey TE; McHugh JB; Spector ME; Brenner JC
Cancer Immunol Immunother; 2019 Feb; 68(2):213-220. PubMed ID: 30361882
[TBL] [Abstract][Full Text] [Related]
10. Intratumoral CD103-positive tumour-infiltrating lymphocytes are associated with favourable prognosis in patients with triple-negative breast cancer.
Park MH; Kwon SY; Choi JE; Gong G; Bae YK
Histopathology; 2020 Oct; 77(4):560-569. PubMed ID: 32333690
[TBL] [Abstract][Full Text] [Related]
11. Resident memory CD8+ T cells within cancer islands mediate survival in breast cancer patients.
Egelston CA; Avalos C; Tu TY; Rosario A; Wang R; Solomon S; Srinivasan G; Nelson MS; Huang Y; Lim MH; Simons DL; He TF; Yim JH; Kruper L; Mortimer J; Yost S; Guo W; Ruel C; Frankel PH; Yuan Y; Lee PP
JCI Insight; 2019 Oct; 4(19):. PubMed ID: 31465302
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Implications of Tumor-Infiltrating Lymphocytes in Association With Programmed Death Ligand 1 Expression in Early-Stage Breast Cancer.
Park IH; Kong SY; Ro JY; Kwon Y; Kang JH; Mo HJ; Jung SY; Lee S; Lee KS; Kang HS; Lee E; Joo J; Ro J
Clin Breast Cancer; 2016 Feb; 16(1):51-8. PubMed ID: 26364145
[TBL] [Abstract][Full Text] [Related]
13. CD103+ intraepithelial T cells in high-grade serous ovarian cancer are phenotypically diverse TCRαβ+ CD8αβ+ T cells that can be targeted for cancer immunotherapy.
Komdeur FL; Wouters MC; Workel HH; Tijans AM; Terwindt AL; Brunekreeft KL; Plat A; Klip HG; Eggink FA; Leffers N; Helfrich W; Samplonius DF; Bremer E; Wisman GB; Daemen T; Duiker EW; Hollema H; Nijman HW; de Bruyn M
Oncotarget; 2016 Nov; 7(46):75130-75144. PubMed ID: 27650547
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study.
Miyashita M; Sasano H; Tamaki K; Hirakawa H; Takahashi Y; Nakagawa S; Watanabe G; Tada H; Suzuki A; Ohuchi N; Ishida T
Breast Cancer Res; 2015 Sep; 17(1):124. PubMed ID: 26341640
[TBL] [Abstract][Full Text] [Related]
15. Characterization of CD103
Han L; Gao QL; Zhou XM; Shi C; Chen GY; Song YP; Yao YJ; Zhao YM; Wen XY; Liu SL; Qi YM; Gao YF
Cancer Immunol Immunother; 2020 Aug; 69(8):1493-1504. PubMed ID: 32285170
[TBL] [Abstract][Full Text] [Related]
16. CD103
Xiao Y; Li H; Mao L; Yang QC; Fu LQ; Wu CC; Liu B; Sun ZJ
J Dent Res; 2019 Dec; 98(13):1480-1487. PubMed ID: 31658426
[TBL] [Abstract][Full Text] [Related]
17. The prognostic value of tumor-infiltrating T lymphocytes in ovarian cancer.
Li J; Wang J; Chen R; Bai Y; Lu X
Oncotarget; 2017 Feb; 8(9):15621-15631. PubMed ID: 28152503
[TBL] [Abstract][Full Text] [Related]
18. The CD4/CD8 ratio of tumor-infiltrating lymphocytes at the tumor-host interface has prognostic value in triple-negative breast cancer.
Wang K; Shen T; Siegal GP; Wei S
Hum Pathol; 2017 Nov; 69():110-117. PubMed ID: 28993275
[TBL] [Abstract][Full Text] [Related]
19. Profound elevation of CD8+ T cells expressing the intraepithelial lymphocyte marker CD103 (alphaE/beta7 Integrin) in high-grade serous ovarian cancer.
Webb JR; Wick DA; Nielsen JS; Tran E; Milne K; McMurtrie E; Nelson BH
Gynecol Oncol; 2010 Sep; 118(3):228-36. PubMed ID: 20541243
[TBL] [Abstract][Full Text] [Related]
20. CD8+CD103+ tumor-infiltrating lymphocytes are tumor-specific tissue-resident memory T cells and a prognostic factor for survival in lung cancer patients.
Djenidi F; Adam J; Goubar A; Durgeau A; Meurice G; de Montpréville V; Validire P; Besse B; Mami-Chouaib F
J Immunol; 2015 Apr; 194(7):3475-86. PubMed ID: 25725111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
